EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BriaCell Therapeutics's enterprise value is $18.63 Mil.
BriaCell Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jan. 2025 was $-27.19 Mil. Therefore, BriaCell Therapeutics's EV-to-EBITDA for today is -0.69.
The historical rank and industry rank for BriaCell Therapeutics's EV-to-EBITDA or its related term are showing as below:
BCTX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.7 Med: 0 Max: 0
Current: -0.69
BCTX's EV-to-EBITDA is ranked worse than 100% of 497
companies
in the Biotechnology industry
Industry Median: 7.69
vs BCTX: -0.69
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
BriaCell Therapeutics EV-to-EBITDA Historical Data
The historical data trend for BriaCell Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BriaCell Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, BriaCell Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BriaCell Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BriaCell Therapeutics's EV-to-EBITDA falls into.
BriaCell Therapeutics's current Enterprise Value is $18.63 Mil.
BriaCell Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BriaCell Therapeutics's PE Ratio (TTM) for today is calculated as:
BriaCell Therapeutics's share price for today is $3.55.
BriaCell Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of BriaCell Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BCTX has been successfully added to your 